TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05335057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR Close Other
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR Close Other
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Close Other
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
Study: NCT06205615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXP154B
Description: BXP154B will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXP154B
Description: BXP154B will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXP154B
Description: BXP154B will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXP154B
Description: BXP154B will be self-administered topically following wound induction
Study: NCT05065541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97489
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97489
Description: Specified dose on specified days
Study: NCT06205615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered topically following wound induction
Study: NCT05065541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T-401
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T-401
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T-401
Description: Specified dose on specified days
Study: NCT06022250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS207
Description: Patients will receive specific dose of JS207 via intravenous infusion.
Study: NCT06516822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI-MLA
Description: The details include: (1) EI-VOM procedure: An 8.5-French-long sheath is inserted into to the CS via the femoral vein. A JR4 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a guide wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated at 6-8 atm pressure in the VOM. Ethanol is infused into VOM from distal to proximal with 3ml each time within 1-2min. After the distal EI-VOM, the balloon is deflated and adjusted to the middle part of VOM. The EI-VOM procedure in the proximal and middle part of VOM should be the same as that in the distal. After three times of EI-VOM, the contrast is injected into VOM to make it permeable and dispersed to observe the effect of alcohol ablation. (2) After EI-VOM, radiofrequency ablation is performed to achieve bilateral PVI, PWI, bidirectional block of MI and CTI, disappearance of LAI-CS potential and SVCI. (3) Any organized AT observed during the procedure is targeted as well.
Study: NCT04952272

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CpG-ODN
Description: CAR-T cells secreting scFv against OX40
Study: NCT05335057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR Alone
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR Alone
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR Alone
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Alone
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR Stranger
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR Stranger
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger
Study: NCT05652608

Intervention type: BEHAVIORAL
Intervention: Immune Strength
Description: Multi-week wellness program provided by the Cleveland Clinic
Study: NCT06323525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)
Description: Phase 1 dose escalation (3+3): dose 1 (1 × 10\^6 cells/kg), dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2: dose of RP2D.
Study: NCT05335057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR Stranger
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Stranger
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Close Other
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Close Other
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Close Other
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Close Other
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
Study: NCT05949385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules
Study: NCT05625802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Description: Up to 30 Cubic Centimeter (cc) of 0.5% ropivacaine administered by local injection into the erector spinae plane under ultrasound guidance
Study: NCT05065541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-3168
Description: Specified dose on specified days
Study: NCT06323525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine 25\~30 mg/m\^2/day on days -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
Study: NCT06055712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Intravenous dose(s).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Intravenous dose(s).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Intravenous dose(s).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Five days oral.
Study: NCT05788926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG6050
Description: Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose.
Study: NCT06650930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate
Description: All participants receive a single, open-label dose of oral calcium carbonate 3000mg
Study: NCT04826224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.
Description: Bone marrow aspirate concentrate contains a median nucleated cell count of 121,700/uL, and platelets of 384,000/uL. This leads to a cellular dose of approximately 400 million cells.
Study: NCT05997979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 8% patch
Description: Patients will receive Capsaicin 8% patch at the inclusion of the study and three months later if it is necessary (persistant pain). Qutenza should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocolloid dressing
Description: Patients will receive Hydrocolloid dressing at the inclusion of the study and three months later if it is necessary (persistant pain). Hydrocolloid dressing should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
Study: NCT06613737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influenza A H3N2 virus dose arm 1
Description: Medium dose, approximately 10\^4.5 TCID50/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influenza A H3N2 virus dose arm 2
Description: High dose, approximately 10\^5.5 TCID50/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influenza A H3N2 virus dose arm 3
Description: TBD, depending on outcome of Part A
Study: NCT05355805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to izokibep
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to izokibep
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study: NCT06615284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvo+™ (Arm1)
Description: Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvo+™ +CBD (Arm 2)
Description: Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvo+™ +CBD (Arm 3)
Description: Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
Study: NCT06617065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Addition of 1 mL of 50% dextrose solution to the usual local anesthetic solution of choice for each patient.
Description: The principal investigator will use a palpation-guided approach to select the injection sites. Injection solutions will be prepared by the assisting nurse. For each patient, 1 mL of a 50% dextrose solution (Pfizer Canada ULS, Kirkland, Québec) will be added to the usual local anesthetic solution of choice.~Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio.
Study: NCT06680479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF chTrimer
Description: Stabilized CH505 TF chTrimer, 300 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: 3 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Suspension
Description: 500 mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride for Injection
Description: Sodium chloride for injection, 0.9% USP volume-matched placebo injection.
Study: NCT05518110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2mg of Trametinib (orally) daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
Study: NCT06622408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HypnoVR© virtual reality headset
Description: Adherence to the use of the virtual reality headset will be reported by a percentage of use at each stage of care.
Study: NCT06683534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin (dietary supplement)
Description: Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to receive placebo will be administered a standard placebo sugar pill.
Study: NCT06626685

Intervention type: OTHER
Intervention: Clinical and instrumental examination
Description: Each patient, consecutively afferent to the SC Cardiologia I of the ASST-PG23 in Bergamo with the diagnosis of acute or chronic HF, at enrollment will undergo to routine clinical and instrumental examination.

Intervention type: OTHER
Intervention: Clinical and instrumental examination
Description: Each patient, consecutively afferent to the SC Cardiologia I of the ASST-PG23 in Bergamo with the diagnosis of acute or chronic HF, at enrollment will undergo to routine clinical and instrumental examination.
Study: NCT06627738

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife irradiation
Description: Additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in inoperable patients with locally advanced non-small cell lung carcinoma
Study: NCT06629285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous compression cryotherapy
Description: Using continuous compression cryotherapy around knee after anterior cruciate ligament reconstruction for 3 postoperative days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ice treatment
Description: Using icepack around knee after anterior cruciate ligament reconstruction for 3 postoperative days
Study: NCT06629077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo an MRI scan while performing breathing and a simulated postural change task.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: A dose of prazosin will be administered based on body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo
Study: NCT06711354

Intervention type: DRUG
Intervention: Anti-CD20 Monoclonal Antibody
Description: Injection of monoclonal anti-CD20 antibody as immunomodulatory treatment of multiple sclerosis
Study: NCT06712524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast-conserving plastic surgery
Description: The commonly used breast conserving plastic surgery includes tennis racket, bat wing, V/J breast plasty, Grisotti and so on.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional breast surgery
Description: Traditional breast surgery
Study: NCT06711718

Intervention type: OTHER
Intervention: Qualitative interview (patients)
Description: Qualitative interviews to be carried out by an experienced researcher with patients who have had their diabetes diagnosis reviewed as a result of the running of the tool.

Intervention type: OTHER
Intervention: Qualitative interview (staff)
Description: Qualitative interviews to be carried out by an experienced researcher with practice staff who have run the tool and reviewed patients flagged by the tool.
Study: NCT06712823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atumelnant (CRN04894)
Description: Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) receptor antagonist.
Study: NCT06712407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TARPEYO®
Description: 6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
Study: NCT06711081

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser device cryotherapy
Description: using new device direct on the pulp tissue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser device cryotherapy
Description: using new device direct on the pulp tissue
Study: NCT06711250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: khoury technique
Description: autogenous bone augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: khoury technique with i-PRF injections
Description: autogenous bone augmentation with repeated i-PRF injections
Study: NCT06714240

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal protein amount
Description: Tube feed containing 1.0 g of protein/kg body weight/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elevated protein amount
Description: Tube feed containing 1.5 g of protein/kg body weight/day
Study: NCT06711913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intravenous dexmedetomidine given in form of 100ml infusion over 10 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: control group receive normal saline as placebo
Study: NCT06712368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: Designed cardiac physical therapy program applied through virtual reality glasses for study group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Designed cardiac physical therapy program
Description: Designed cardiac physical therapy program without virtual reality glasses
Study: NCT06711965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care reconstruction
Description: Participants will receive standard of care reconstruction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery, Breast Mold
Description: Participants will undergo surgery. The surgeon may utilize the custom breast mold in shaping the autologous tissue flap for particiapnts.
Study: NCT06709339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab Injection [Vabysmo]
Description: The investigational medicinal product (IMP) for this study is faricimab (RO6867461), as per clinical practice. No control treatment will be used for this study
Study: NCT06714279

Intervention type: DRUG
Group type: OTHER
Intervention: Tap Block - Bupivacaine
Description: The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intraperitoneal infiltration to liver
Description: The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
Study: NCT06421597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: prednisoline 25 mg/day for seven days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment for seven days
Study: NCT06044649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT endorses a pain management model and teaches people skills to cope with chronic pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.
Study: NCT03952481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.